Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells

Hepatology

Volumn 41, Issue 4, 2005, Pages 722-730

  Unitt, Esther ^a   Rushbrook, Simon M ^a   Marshall, Aileen ^a   Davies, Susan ^b   Gibbs, Paul ^c   Morris, Lesley S ^d   Coleman, Nicholas ^d   Alexander, Graeme J M ^a,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL CYCLE; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; HUMANS; KI-67 ANTIGEN; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 16244393380     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20644     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001;94:153-156.
2. O'Grady J, Lake JR, Howdle PD. Malignant tumours of the liver. In: O'Grady JG, Lake JR, Howdle PD, eds. Comprehensive Clinical Hepatology. London: Harcourt Publishers, 2000:25.21-25.18.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver Transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-700.
5. Dick EA, Taylor-Robinson SD, Thomas HC, Gedroyc WMW. Ablative therapy for liver tumours. Gut 2002;50:733-739.
6. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002;50:881-885.
7. Foss FM. Immunologic mechanisms of antitumour activity. Semin Oncol 2002;29:5-11.
8. Chavan SS, Chiplunkar SV. Immunophenotypes and cytotoxic functions of lymphocytes in patients with hepatocellular carcinoma. Tumori 1997;83:762-767.
9. Wada Y, Nakashima O, Kurami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. HEPATOLOGY 1998;27:407-414.
10. Kawata A, Une Y, Hosokawa M, Uchino J, Kobayashi H. Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma. Jpn J Clin Oncol 1992;22:256-263.
11. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Yves Blay J. The host-tumour immune conflict: from immunosuppression to resistance and destruction. Immunology Today 1997;18:493-499.
12. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167:1137-1140.
13. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296.
14. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, et al. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human rhymocytes. J Exp Med 2002;196:379-387.
15. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003;4:337-342.
16. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
17. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003;112:1437-1443.
18. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285-1294.
19. Baecher-Allen C, Brown JA, Freeman GJ, Haffler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-1253.
20. Oida T, Zhang X, Goto M, Hachimura S, Totsuka M, Kaminogawa S, et al. CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol 2003;170:2516-2522.
21. Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S A 2003;100:10878-10883.
22. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, et al. TGF-beta1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004;172:834-842.
23. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001;194:629-644.
24. Shevach EM. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
25. Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25+ T cells. Immunology 2002;107:5-9.
26. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumour microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761.
27. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, et al. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-4276.
28. Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 2002;62:5267-5272.
29. Onizuka S, Tawara I, Shimizu S, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59:3128-3133.
30. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-5218.
31. Jones E, Dahm-Vicker M, Simon A, Green A, Powrie F, Cerundolo V, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1-12.
32. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999;5:2121-2132.
33. Rodins K, Cheale M, Coleman N, Fox SB. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumour dormancy and potential clinical utility. Clin Cancer Res 2002;8:1075-1081.
34. Akhurst RJ. TGF-beta antagonists: why suppress a tumor suppressor? J Clin Invest 2002;109:1533-1536.
35. Baisch H, Gerdes J. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet 1987;20:387-391.
36. Tomiyama H, Matsuda T, Takiguchi M. Differentiation of human CD8(+) T cells from a memory to memory/effector phenotype. J Immunol 2002;168:5538-5550.
37. Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, et al. Lack of terminally differentiated tumour-specific CD8+ T cells at tumour site in spite of antitumour immunity to self-antigens in human metastatic melanoma. Cancer Res 2003;63:2535-2545.
38. Fu S, Yopp AC, Mao X, Chen D, Zhang N, Mao M, et al. CD4+CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant 2004;4:65-78.
39. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-612.
40. Yoong K, Afford S, Jones R, Aujla P, Qin S, Price K, et al. Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. HEPATOLOGY 1999;30:100-111.
41. Chen S, Akbar SM, Tanimoto K, Ninomiya T, Iuchi H, Michitaka K, et al. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett 2000;148:49-57.
42. Yamauchi K, Akbar SM, Horiike N, Michitaka K, Onji M. Increased serum levels of macrophage inflammatory protein-3alpha in hepatocellular carcinoma: relationship with clinical factors and prognostic importance during therapy. Int J Mol Med 2003;11:601-605.
43. Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N, et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999;162:4567-4575.
44. Giannelli G, Fransvea E, Marinosci F, Bergamini C, Colucci S, Schiraldi O, et al. Transforming growth factor-beta 1 triggers hepatocellular caarcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 2002;161:183-193.
45. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-612.
46. Zheng SG, Gray JD, Ohtsuka K, Yamagiwa S, Horwitz DA. Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors. J Immunol 2002;169:4183-4189.
47. Camara NO, Sebille F, Lechler RI. Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol 2003;33:3473-3483.